SonarMed, New Pediatric Monitor Alerts Clinicians To Potential Airway Obstructions During Ventilation Launched

SonarMed airway monitoring system is the first and only device of its kind.

SonarMed airway monitoring system utilizes acoustic technology to check for endotracheal tube (ETT) obstruction and verify position in real-time, giving clinicians vital information required to make more informed, life-saving decisions for their smallest patients.

Globally, 415,000 neonates and infants require invasive mechanical ventilation per year and are intubated for greater than 24 hours. Despite recommendations and reduction efforts, 75,000, or about one in five, of these neonates and infants will experience at least one unplanned extubation (UE). In the NICU, UEs are a significant safety concern for neonates and newborns and are the most common adverse event during mechanical ventilation.1 These events can lead to increased length of stay and hospital costs.2 Adoption of the SonarMed airway monitoring system can help reduce the frequency of these events, which in turn can help improve outcomes and reduce healthcare costs.

“The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded,” said Jamie W. Powers, M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California.

He added, “At our hospital, this information has led to a drastic reduction in the number of x-rays performed and marked improvement in the effective suctioning of the airway. It also provides the care team and parents the added reassurance that the breathing tube is where it needs to be while repositioning the patient and during kangaroo care. In our institution it has become the new standard of care for all intubated infants.”

The SonarMed airway monitoring system is the first and only FDA-cleared airway monitoring system that provides timely notifications and specific measurements that help enable a coordinated response to address potentially critical events such as ETT movement and migration.

“Clinicians face unique challenges in the neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU) daily, ranging from managing oxygenation within extremely tight ranges, to keeping family members informed and comforted. With our innovative technology, this fragile patient group is continuously monitored with a real-time and accurate device that may help improve a clinician’s ability to manage the airway and enhance outcomes for our smallest, most vulnerable critical care patients,” said Ariel MacTavish, president of the Respiratory Interventions business, which is part of the Medical Surgical Portfolio at Medtronic.

MacTavish concluded, “Our goal with introducing the SonarMed technology is to help solve a clinical need to reduce the number of unplanned extubations to help these vulnerable patients start their lives in the healthiest way.”

SonarMed, which was acquired by Medtronic in December 2020, specializes in developing solutions that increase patient safety while significantly decreasing healthcare costs.

“With Medtronic’s extensive market presence, clinical leadership, and market development expertise, coupled with SonarMed’s innovative technology, we are confident that together, we can potentially help save the lives of thousands of infants,” said Tom Bumgardner, strategic planning program director, Medtronic Respiratory Interventions, and former SonarMed CEO.

SourceMedtronic
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version